Skip to main content

Table 1 Demographic and clinical characteristics of patients during the 12 months prior to initiating ALIS

From: Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings

 

ALIS cohort

(N = 331)

Age, mean (SD), years

64.6 (16.0)

Age categories, n (%)

   18 − 24 years

17 (5.1)

   25 − 34 years

10 (3.0)

   35 − 44 years

12 (3.6)

   45 − 54 years

14 (4.2)

   55 − 64 years

71 (21.5)

   65 − 74 years

115 (34.7)

   75 + years

92 (27.8)

Sex, n (%)

   Female

258 (77.9)

   Male

73 (22.1)

Health insurance, n (%)

   Commercial

92 (27.8)

   Medicare

218 (65.9)

   Medicaid

21 (6.3)

US geographic region, n (%)

   Northeast

74 (22.4)

   North Central

42 (12.7)

   South

152 (45.9)

   West

63 (19.0)

CCI, mean (SD)

2.2 (2.0)

Smoking history, n (%)

64 (19.3)

Pulmonary comorbidities/symptoms, n (%)

   NTM-LD

263 (79.5)

Other pulmonary comorbidities and symptoms

311 (94.0)

   Bronchiectasis

189 (57.1)

   COPD

151 (45.6)

   Dyspnea

132 (39.9)

   Cough

125 (37.8)

   Asthma

74 (22.4)

   Emphysema

51 (15.4)

   Hemoptysis

44 (13.3)

   Cystic fibrosis with pulmonary manifestations

33 (10.0)

   Aspergillosis

28 (8.5)

   Idiopathic pulmonary fibrosis

27 (8.2)

   Idiopathic interstitial lung disease

19 (5.7)

   Malignant neoplasm of bronchus and lung

15 (4.5)

   Simple and mucopurulent chronic bronchitis

15 (4.5)

   Diffuse panbronchiolitis

8 (2.4)

   Pulmonary tuberculosis

7 (2.1)

   Lung transplant

6 (1.8)

   Pneumonia

2 (0.6)

Non-pulmonary comorbidities, n (%)

274 (82.8)

   Cardiovascular disease

195 (58.9)

   Hypertension

138 (41.7)

   Gastroesophageal reflux

97 (29.3)

   Osteoporosis

60 (18.1)

   Diabetes mellitus

59 (17.8)

   Other cancers

42 (12.7)

   Underweight

39 (11.8)

   Malnutrition

38 (11.5)

   Chronic kidney disease

30 (9.1)

   Other NTM diseasea

24 (7.3)

   Chronic heart failure

15 (4.5)

   Overweight and obesity

11 (3.3)

   Rheumatoid arthritis

10 (3.0)

   Transplant of kidney or liver

7 (2.1)

   Sjögren syndrome

5 (1.5)

   HIV/AIDS

2 (0.6)

   Dementia

1 (0.3)

  1. ALIS amikacin liposome inhalation suspension, CCI Charlson Comorbidity Index, COPD chronic obstructive pulmonary disease, DMAC disseminated mycobacterium avium-intracellulare complex, HIV/AIDS human immunodeficiency syndrome virus/acquired immunodeficiency syndrome, NTM nontuberculous mycobacterial, NTM-LD nontuberculous mycobacterial lung disease; TB tuberculosis
  2. aOther NTM disease included cutaneous mycobacterial infection and DMAC